Changes in prostate cancer at radical prostatectomy during the prostate specific antigen era: An Italian experience

Analytical and Quantitative Cytology and Histology

Volumn 30, Issue 3, 2008, Pages 152-159

  Bollito, Enrico ^a   Terrone, Carlo ^b   Volpe, Alessandro ^a   Porpiglia, Francesco ^a   Cracco, Cecilia ^a   Poggio, Massimiliano ^a   Grande, Susanna ^c   Righi, Luisella ^c   Bellina, Maurizio ^c   Papotti, Mauro ^c   Scarpa, Roberto Mario ^c  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c NONE

Author keywords

Pathology; Prostate cancer; Prostatectomy, radical; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER LOCALIZATION; CLINICAL FEATURE; DIAGNOSTIC VALUE; EXPERIENCE; HUMAN; ITALY; LAPAROSCOPIC SURGERY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE DISEASE; TUMOR VOLUME;

ADENOCARCINOMA; AGED; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REFERENCE VALUES; SEMINAL VESICLES;

EID: 44949211531     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Catalona WJ, Loeb S, Han M: Viewpoint: Expanding prostate cancer screening. Ann Intern Med 2006;144:441-443
2. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, Wolff J, Zattoni F; European Association of Urology: EAU guidelines on prostate cancer. Eur Urol 2005;48:546-551
3. Stephenson RA: Population-based prostate cancer trends in the PSA era: Data from the Surveillance, Epidemiology and End Results (SEER) program. Monogram Urol 1998;19:3-19
4. Farkas A, Schneider D, Perrotti M, Cummings KB, Ward WS: National trends in the epidemiology of prostate cancer, 1973 to 1994: Evidence for the effectiveness of prostate-specific antigen screening. Urology 1998;52:444-448, discussion 8-9
5. Boccardo F, Ciatto S, Martorana G: Italian national consensus conference on prostate cancer screening (Florence, May 17, 2003): Final consensus document. Int J Biol Markers 2003;18:238-240
6. Lopez-Beltran A, Bollito E, Luque RJ, Montironi R: A practical approach to bladder sampling and diagnostic reporting of pathological findings. Pathologica 2001;93:688-692
7. Stamey TA, McNeal JE, Freiha FS, Redwine E: Morphometry and clinical studies on 68 consecutive radical prostatectomies. J Urol 1988;139:1235-1241
8. D'Ambrosio G, Samani F, Cancian M, De Mola C: Practice of opportunistic prostate-specific antigen screening in Italy: Data from the Health Search database. Eur J Cancer Prev 2004;13:383-386
9. Melia J, Moss S, Johns L: Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: A cross-sectional study. BJU Int 2004;94:51-56
10. Gerber GS, Thisted RA, Scardino PT, Frohmuller HG, Schroeder FH, Paulson DF, Middleton AW Jr, Rukstalis DB, Smith JA Jr, Schellhammer PF, Ohori M, Chodak GW: Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 1996;276:615-619
11. Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC: Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001;166:416-419
12. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J: The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years? J Urol 2004;172:1297-1301
13. Bott SR, Freeman AA, Stenning S, Cohen J, Parkinson MC: Radical prostatectomy: Pathology findings in 1001 cases compared with other major series and over time. BJU Int 2005;95:34-39
14. Quinn DI, Henshall SM, Haynes AM, Brenner PC, Kooner R, Golovsky D, Mathews J, O'Neill GF, Turner JJ, Delprado W, Finlayson JF, Sutherland RL, Grygiel JJ, Stricker PD: Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: Implications for staging systems and predictive models. J Clin Oncol 2001;19:3692-3705
15. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167:528-534
16. Jang TL, Han M, Roehl KA, Hawkins SA, Catalona WJ: More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects. Urology 2006;67:343-348
17. Ung JO, Richie JP, Chen MH, Renshaw AA, D'Amico AV: Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 2002;60:458-463
18. Catalona WJ, Smith DS: Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-term results. J Urol 1998;160:2428-2434
19. Salomon L, Levrel O, Anastasiadis AG, Katz R, Irani J, De la Taille A, Saint F, Vordos D, Cicco A, Hoznek A, Chopin D, Abbou CC: Prognostic significance of tumor volume after radical prostatectomy: A multivariate analysis of pathological prognostic factors. Eur Urol 2003;43:39-44
20. Krumholtz JS, Carvalhal GF, Ramos CG, Smith DS, Thorson P, Yan Y, Humphrey PA, Roehl KA, Catalona WJ: Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology 2002;60:469-473, discussion 73-74
21. Watson RB, Civantos F, Soloway MS: Positive surgical margins with radical prostatectomy: Detailed pathological analysis and prognosis. Urology 1996;48:80-90
22. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM: Biological determinants of cancer progression in men with prostate cancer. JAMA 1999;281:1395-1400
23. Renshaw AA, Richie JP, Loughlin KR, Jiroutek M, Chung A, D'Amico AV: Maximum diameter of prostatic carcinoma is a simple, inexpensive, and independent predictor of prostate-specific antigen failure in radical prostatectomy specimens: Validation in a cohort of 434 patients. Am J Clir. Pathol 1999;111:641-644
24. Ohori M, Abbas F, Wheeler TM, Kattan MW, Scardino PT, Lerner SP: Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology. J Urol 1999;161:500-504
25. Epstein JI, Carmichael M, Partin AW, Walsh PC: Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol 1993;149:1478-1481
26. Kikuchi E, Scardino PT, Wheeler TM, Slawin KM, Ohori M: Is tumor volume an independent prognostic factor in clinically localized prostate cancer? J Urol 2004;172:508-511
27. Bostwick DG, Grignon DJ, Hammond ME, Amin MB, Cohen M, Crawford D, Gospadarowcz M, Kaplan RS, Miller DS, Montironi R, Pajak TF, Pollack A, Srigley JR, Yarbro JW: Prognostic factors in prostate cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:995-1000
28. Jack GS, Cookson MS, Coffey CS, Vader V, Roberts RL, Chang SS, Smith JA Jr, Shappell SB: Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: Decreased pathological stage and increased detection of transition zone tumors. J Urol 2002;168:519-524
29. Carter HB, Epstein JI, Chan DW, Fozard JL, Pearson JD: Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 1997;277:1456-1460
30. Cheng L, Poulos CK, Pan CX, Jones TD, Daggy JK, Eble JN, Koch MO: Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens. J Urol 2005;174:898-902
31. Augustin H, Hammerer PG, Graefen M, Erbersdoler A, Blonski J, Palisaar J, Daghofer F, Huland H: Insignificant prostate cancer in radical prostatectomy specimen: Time trends and preoperative prediction. Eur Urol 2003;43:455-460
32. Ciatto S, Gervasi G, Bonardi R, Frullini P, Zendron P, Lombardi C, Crocetti E, Zappa M: Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991-1994). Eur J Cancer 2005;41:411-415
33. Stamey TA, Donaldson AN, Yemoto CE, McNeal JE, Sozen S, Gill H: Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: Epidemiologic significance of annual changes. J Urol 1998;160:2412-2417
34. Soh S, Kattan MW, Berkman S, Wheeler TM, Scardino PT: Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol 1997;157:2212-2218